P. D. van Poelje

发表

Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.

W. Lipscomb, M. Erion, Q. Dang, 2007, Journal of the American Chemical Society.

P. D. van Poelje, E. Snell, 1990, Annual review of biochemistry.

Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.

M. Erion, Q. Dang, S. Kasibhatla, 2011, Journal of medicinal chemistry.

Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys

M. Erion, P. D. van Poelje, D. Mackenna, 2009, British journal of pharmacology.

Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats

M. Erion, Q. Dang, P. D. van Poelje, 2006, Diabetes.

Reduction of hepatic steatosis in rats and mice after treatment with a liver‐targeted thyroid hormone receptor agonist

M. Erion, P. D. van Poelje, E. Cable, 2009, Hepatology.

Site-directed alteration of the active-site residues of histidine decarboxylase from Clostridium perfringens.

P. D. van Poelje, A. Kamath, E. Snell, 1990, Biochemistry.

Liver-Targeted Drug Delivery Using HepDirect1 Prodrugs

M. Erion, P. D. van Poelje, D. Mackenna, 2005, Journal of Pharmacology and Experimental Therapeutics.

Use of p-aminobenzoic acid and tritiated cyanoborohydride for the detection of pyruvoyl residues in proteins.

P. D. van Poelje, E. Snell, 1987, Analytical biochemistry.

Amine cations promote concurrent conversion of prohistidine decarboxylase from Lactobacillus 30a to active enzyme and a modified proenzyme.

P. D. van Poelje, E. Snell, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index

Hongjian Jiang, M. Erion, P. D. van Poelje, 2007, Proceedings of the National Academy of Sciences.

Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver.

M. Erion, P. D. van Poelje, K. R. Reddy, 2004, Journal of the American Chemical Society.

Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection.

M. Erion, P. D. van Poelje, M. Maccoss, 2007, Journal of medicinal chemistry.

Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.

M. Erion, Q. Dang, P. D. van Poelje, 2009, Journal of medicinal chemistry.

Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.

M. Erion, P. D. van Poelje, K. R. Reddy, 2008, Journal of medicinal chemistry.

Synthesis of phosphonate 3-phthalidyl esters as prodrugs for potential intracellular delivery of phosphonates.

M. Erion, Q. Dang, P. D. van Poelje, 1999, Bioorganic & medicinal chemistry letters.

Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.

M. Erion, Q. Dang, S. Kasibhatla, 2010, Journal of medicinal chemistry.

MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes

Tao Jiang, M. Rami Reddy, Mark D. Erion, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.

W. Lipscomb, M. Erion, Q. Dang, 2007, Journal of the American Chemical Society.

Bis[(para-methoxy)benzyl] phosphonate prodrugs with improved stability and enhanced cell penetration.

M. Erion, Q. Dang, P. D. van Poelje, 2007, Bioorganic & medicinal chemistry letters.

Antiviral Efficacy upon Administration of a HepDirect Prodrug of 2′-C-Methylcytidine to Hepatitis C Virus-Infected Chimpanzees

M. Erion, P. D. van Poelje, M. Maccoss, 2009, Antimicrobial Agents and Chemotherapy.

Preclinical Pharmacokinetics of a HepDirect Prodrug of a Novel Phosphonate-Containing Thyroid Hormone Receptor Agonist

M. Erion, P. D. van Poelje, E. Cable, 2008, Drug Metabolism and Disposition.

LIVER TARGETING OF HEPATITIS-B ANTIVIRAL LAMIVUDINE USING THE HEPDIRECT™ PRODRUG TECHNOLOGY

M. Erion, P. D. van Poelje, K. R. Reddy, 2005, Nucleosides, nucleotides & nucleic acids.

Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.

M. Erion, P. D. van Poelje, Paul D. van Poelje, 2011, Handbook of experimental pharmacology.

Isolation of a family of organic anion transporters from human liver and kidney.

M. Erion, P. D. van Poelje, W. Sun, 2001, Biochemical and biophysical research communications.

A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis.

M. Erion, Q. Dang, P. D. van Poelje, 2010, ACS medicinal chemistry letters.

Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.

M. Erion, Q. Dang, S. Kasibhatla, 2008, Journal of medicinal chemistry.

The riddle of formycin A insulinotropic action.

P. Rorsman, P. D. van Poelje, W. Malaisse, 1996, Biochemical and Molecular Medicine.

Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.

M. Erion, P. D. van Poelje, S. Potter, 2011, Handbook of experimental pharmacology.

The allosteric site of human liver fructose-1,6-bisphosphatase. Analysis of six AMP site mutants based on the crystal structure.

M. Erion, P. D. van Poelje, S. Pilkis, 1995, The Journal of biological chemistry.

Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes.

M. Erion, Q. Dang, P. D. van Poelje, 2007, Current opinion in drug discovery & development.